Lovisa Berggren
About
Lovisa Berggren is a scholar working on Psychiatry and Mental health, Pharmacology and Cognitive Neuroscience.
According to data from OpenAlex, Lovisa Berggren has authored 27 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 9 papers in Pharmacology and 6 papers in Cognitive Neuroscience. Recurrent topics in Lovisa Berggren's work include Treatment of Major Depression (8 papers), Attention Deficit Hyperactivity Disorder (7 papers) and Psoriasis: Treatment and Pathogenesis (6 papers). Lovisa Berggren is often cited by papers focused on Treatment of Major Depression (8 papers), Attention Deficit Hyperactivity Disorder (7 papers) and Psoriasis: Treatment and Pathogenesis (6 papers). Lovisa Berggren collaborates with scholars based in United States, Germany and United Kingdom. Lovisa Berggren's co-authors include Catherine Datto, Hans Eriksson, O Hansson, Martín Dossenbach, Jitendra Patel, Yves Dutronc, Chris Bushe, L. Puig, Heikki Katila and Willie Earley and has published in prestigious journals such as The Lancet, Journal of Investigative Dermatology and Psychiatry Research.
In The Last Decade
Lovisa Berggren
27 papers receiving 378 citations
Peers
Lovisa Berggren
Jean‐Michel Germain United States
Doron Mazeh Israel
Elena Kornyeyeva United States
Ziyan Fang China
Alina Wilkowska Poland
Nicoletta Carlo-Stella Italy
Ashley H. Robins South Africa
Nicole Lichtblau Germany
Katarzyna Curzytek Poland
Citations per year, relative to Lovisa Berggren Lovisa Berggren (= 1×)
peers
Jean‐Michel Germain
Countries citing papers authored by Lovisa Berggren
Since
Specialization
Citations
This map shows the geographic impact of Lovisa Berggren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lovisa Berggren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lovisa Berggren more than expected).
Fields of papers citing papers by Lovisa Berggren
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lovisa Berggren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lovisa Berggren. The network helps show where Lovisa Berggren may publish in the future.
Co-authorship network of co-authors of Lovisa Berggren
This figure shows the co-authorship network connecting the top 25 collaborators of Lovisa Berggren. A scholar is included among the top collaborators of Lovisa Berggren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lovisa Berggren. Lovisa Berggren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Puig, L., Mark Lomaga, Kristin Hollister, et al.. (2020). An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis. Acta Dermato Venereologica. 100(19). adv00344–adv00344.
2.
Wasel, Norman, Diamant Thaçi, Lars E. French, et al.. (2020). Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatology and Therapy. 10(4). 663–670.
3.
Puig, L., Martín Dossenbach, Lovisa Berggren, Anders Ljungberg, & Claus Zachariae. (2019). Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes. Acta Dermato Venereologica. 99(11). 971–977.
4.
Yosipovitch, Gil, Adam Reich, Martin Steinhoff, et al.. (2018). Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies. Dermatology and Therapy. 8(4). 621–637.
5.
Rouillon, F., et al.. (2017). Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation. L Encéphale. 43(4). 303–310.
6.
Fernández‐Peñas, Pablo, Orin M. Goldblum, Lovisa Berggren, Nicole Y. Burkhardt, & D. Jullien. (2017). 337 Long-term clinical outcomes after 2 years of Ixekizumab treatment in patients with moderate-to-severe psoriasis with a focus on absolute PASI. Journal of Investigative Dermatology. 137(5). S58–S58.
7.
Anand, Ernie, et al.. (2016). Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being. Neuropsychiatric Disease and Treatment. Volume 12. 2737–2743.
8.
Bushe, Chris, et al.. (2016). Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database. CNS Drugs. 30(4). 317–334.
9.
Bushe, Chris, et al.. (2016). Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database. CNS Drugs. 30(6). 541–558.
10.
Anand, Ernie, et al.. (2015). A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation. Neuropsychiatric Disease and Treatment. 11. 1349–1349.
11.
Sheehan, David V., Michele Mancini, Jianing Wang, et al.. (2015). Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors. Human Psychopharmacology Clinical and Experimental. 31(1). 53–63.
12.
Asherson, Philip, Steven Stes, Lovisa Berggren, et al.. (2015). The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies. European Psychiatry. 30(4). 511–520.
13.
Sobanski, Esther, Sami Leppämäki, Chris Bushe, et al.. (2015). Patterns of long-term and short-term responses in adult patients with attention-deficit/hyperactivity disorder in a completer cohort of 12 weeks or more with atomoxetine. European Psychiatry. 30(8). 1011–1020.
14.
Romera, Irene, Víctor Pérez, Deborah Quail, et al.. (2014). Individual residual symptoms and functional impairment in patients with depression. Psychiatry Research. 220(1-2). 258–262.
15.
Schacht, Alexander, et al.. (2014). Impact of Pretreatment With Antidepressants on the Efficacy of Duloxetine in Terms of Mood Symptoms and Functioning. The Primary Care Companion For CNS Disorders. 16(5).
16.
Ziegler, Dan, Edith Schneider, Frank Boess, Lovisa Berggren, & Frank Birklein. (2014). Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice. Journal of Diabetes and its Complications. 28(5). 698–704.
17.
Schacht, Alexander, et al.. (2014). Does Early Improvement in Anxiety Symptoms in Patients with Major Depressive Disorder Affect Remission Rates? A Post-Hoc Analysis of Pooled Duloxetine Clinic Trials. 3(3). 112–123.
18.
Katila, Heikki, et al.. (2013). Randomized, Double-Blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Elderly Patients with Major Depressive Disorder. American Journal of Geriatric Psychiatry. 21(8). 769–784.
19.
Ciudad, Antonio, et al.. (2013). Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses. Neuropsychiatric Disease and Treatment. 9. 1737–1737.
20.
Datto, Catherine, Lovisa Berggren, Jitendra Patel, & Hans Eriksson. (2009). Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: A randomized, double-blind, crossover study in healthy adult subjects. Clinical Therapeutics. 31(3). 492–502.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jean‐Michel Germain Breakdown of academic impact, for papers by Doron Mazeh Breakdown of academic impact, for papers by Elena Kornyeyeva Breakdown of academic impact, for papers by Ziyan Fang Breakdown of academic impact, for papers by Alina Wilkowska Breakdown of academic impact, for papers by Arafat Hussein Al-Dujaili Breakdown of academic impact, for papers by Nicoletta Carlo-Stella Breakdown of academic impact, for papers by Ashley H. Robins Breakdown of academic impact, for papers by Nicole Lichtblau Breakdown of academic impact, for papers by Katarzyna Curzytek